Fig. 2.

Both BRAF wildtype and mutant melanoma cells are more sensitive to irreversible multi-erbB inhibitors canertinib than single-erbB or dual-erbB targeting agents. Dose-dependent response curves of growth inhibition in BRAF WT (a) and V600E mutant (b) cells by 3-day treatment of gefitinib, lapatinib, erlotinib, and canertinib. Cell viability after each drug treatment was assessed by MTT assay compared with vehicle control treatment and expressed as percent vehicle control (% control). n = 3–4 experiments. WT, wildtype.